SCHEMBL13247010

SCHEMBL13247010

c1c[nH]c(C(c2cnc[nH]2)c2cccc3ncccc23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 10/20 0.45
ADRA2B P18089 10/20 0.45
ADRA2C P18825 10/20 0.45
ADRA1A P35348 7/20 0.45
ADRA1B P35368 6/20 0.45
ADRA1D P25100 5/20 0.45
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
KCNH2 Q12809 1/20 0.37
TP53 P04637 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
SLC6A2 P23975 1/20 0.36
HTR7 P34969 1/20 0.36
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
ACVR1 Q04771 2/20 0.33
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700313 0.84 ADRA2A (0.49) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL3026572 0.84 ADRA2A (0.49) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL13247041 0.84 ADRA2A (0.46) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL13247045 0.82 SLC6A3 (0.42) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL13247040 0.82 ADRA2A (0.45) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL13247044 0.82 MAPT (0.45) ADRA2AADRA2BADRA2CCYP3A4TSHR
SCHEMBL13247046 0.82 SLC6A3 (0.37) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL13247001 0.81 ADRA2A (0.44) ADRA2AADRA2BADRA2CADRA1AADRA1B
SCHEMBL10000105 0.81 KDM4E (0.40) CYP3A4SLC6A2KDM4EMAPTACVR1
SCHEMBL10000100 0.81 ADRA2A (0.43) ADRA2AADRA2BADRA2CADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162450-B1 ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS ALLERGAN INC (US) 2015-02-25 EP disclosed
US-8383646-B2 Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-8383646-B2 Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-20100190823-A1 Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds ALLEGERGAN INC. (US) 2010-07-29 US disclosed
US-20100190823-A1 Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds ALLEGERGAN INC. (US) 2010-07-29 US disclosed
WO-2008147786-A1 ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS ALLERGAN, INC. (US) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190823-A1 Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds OAT, HMGCR, GOT2 ADRA2A 1446/4885ADRA2B 1766/4885ADRA2C 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.